Mizuho lowered the firm’s price target on Apellis (APLS) to $20 from $30 and keeps a Neutral rating on the shares. The firm reduced its view for the company’s lead asset Syfovre for geographic atrophy. Due to several factors, including lingering safety questions, potentially stalling growth for the class, and the negative impact from recent changes to patient co-pay assistance programs, Mizuho now envisions “persistent challenges” for Syfovre’s uptake.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APLS:
- Buy Recommendation for Apellis Pharmaceuticals Driven by Syfovre’s Market Potential and Strategic Expansion
- Qualcomm initiated, Lyft upgraded: Wall Street’s top analyst calls
- Apellis downgraded to Neutral from Buy at BofA
- Apellis downgraded to Outperform from Strong Buy at Raymond James
- Apellis price target lowered to $20 from $28 at Scotiabank
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue